The new European Regulation on Clinical Trials: An opportunity for Belgium to consolidate its leading position

Pharma.be and BeAPP have the pleasure of inviting you to an info-evening on ?The new European regulation on clinical trials: an opportunity for Belgium to consolidate its leading position?, on Wednesday 21 May from 5.30 PM till 8.00 PM. Program 5.30 PM Welcoming drink 5.45 PM Introduction Catherine Rutten, CEO pharma.be Stefaan Vancayzeele, President BeAPP & Secretary BCPM 5.55 PM ?The new European regulation on clinical trials on medicinal products for human use: key elements in a nutshell ? Monique Podoor, The Initiative To Promote Clinical Trials In Belgium Nathalie Lambot, Expert Clinical Trials & Regulatory Affairs pharma.be 6.10 PM ?The new European regulation on clinical trials: what does it mean for Belgium? ? Nathalie Lambot, Expert Clinical Trials & Regulatory Affairs pharma.be Monique Podoor, The Initiative To Promote Clinical Trials In Belgium 6.25 PM ?FAMHP strategy integrated into a changing European regulatory framework ? : short presentations??General policy towards critical points of attention ? Greet Musch, Director-General DG Pre FAMHP ?Working processes and EU portal ? Kristof Bonnarens, Head of Division R&D FAMHP & member CTFG ?Domain of Excellence Early Phase Development ? Walter Janssens , Domain of Excellence Coordinator FAMHP & member SAWP 6.40 PM Questions & Answers 6.55 PM Interactive exchange of views Catherine Rutten, CEO pharma.be Stefaan Vancayzeele, President BeAPP & Secretary BCPM Greet Musch, Director-General DG Pre FAMHP Omer Van Schoor, Secretary BAPU Yves Geysels, President ACRP 7.25 PM Cocktail & networking The info-evening will take place in English. You will have the opportunity to ask your questions in your native language.

Share with others